Trisalus Life Sciences, INC Form 4 insider transactions

TriSalus Life Sciences' Chief Regulatory Officer, Jennifer Stevens, was granted 50,000 restricted stock units and 100,000 employee stock options.

TriSalus Life Sciences' Chief Commercial Officer, Richard Marshak, was granted 60,000 restricted stock units and 120,000 employee stock options.

TriSalus Life Sciences' Chief Financial Officer, David Patience, was granted 65,000 restricted stock units and 130,000 employee stock options.

TriSalus Life Sciences' CFO, David Patience, received 248,899 performance-based stock options tied to a $75 million revenue target.

TriSalus Life Sciences, Inc. Chief Financial Officer David Patience received grants of 200,000 restricted stock units and 290,000 employee stock options.

Arjun JJ Desai, a Director at TriSalus Life Sciences, Inc., was granted 15,000 stock options with an exercise price of $5.50 per share.

TriSalus Life Sciences, Inc. Director Gary B. Gordon was granted 15,000 stock options with an exercise price of $5.50, set to vest over one year or by the next annual stockholder meeting.

TriSalus Life Sciences, Inc. Director Kerry R. Hicks was granted 15,000 stock options with an exercise price of $5.50, vesting over one year or at the next annual stockholder meeting.

TriSalus Life Sciences, Inc. Director David J. Matlin was granted 15,000 stock options with an exercise price of $5.5, vesting over one year or upon the next annual stockholder meeting.

TriSalus Life Sciences, Inc. Director Sean Murphy was granted 15,000 stock options with an exercise price of $5.50, increasing his total beneficial ownership of derivative securities to 554,681.

TriSalus Life Sciences, Inc. Director William Valle was granted 15,000 stock options with an exercise price of $5.50, vesting over one year or at the next annual stockholder meeting.

TriSalus Life Sciences, Inc. Director Mats Wahlstrom was granted 15,000 stock options with an exercise price of $5.50, vesting over one year or upon the next annual stockholder meeting.

James Emmett Young, CFO of TriSalus Life Sciences, reports acquisition of common stock and holdings in a living trust.

Bryan F. Cox, Chief of Research at TriSalus Life Sciences, reports acquiring and disposing of common stock on May 19, 2025, to cover tax liabilities associated with vested Restricted Stock Units (RSUs).

Jodi Devlin, Chief of Clinical Operations at TriSalus Life Sciences, reports acquisition and disposal of common stock related to vested RSUs.

Richard Marshak, Chief Commercial Officer of TriSalus Life Sciences, reports acquisition and disposal of common stock related to vested RSUs.

Director Sean Murphy reports acquiring shares of TriSalus Life Sciences, Inc. through restricted stock units.

Jennifer Stevens, Chief Regulatory Officer of TriSalus Life Sciences, reports acquisition and disposal of common stock on May 19, 2025.

TriSalus Life Sciences secures $22 million in private placement and reports preliminary Q1 2025 revenue growth of 42%, aiming to advance its oncology-focused medical technology.

Sean Murphy, Chief Manufacturing, Strategy & Business Development Officer at TriSalus Life Sciences, reports acquisition and disposal of common stock and a grant of restricted stock units.

James Emmett Young, CFO of TriSalus Life Sciences, reports the acquisition of 14,762 shares of common stock and the disposal of 30,000 shares held indirectly through a trust.

Jennifer Stevens, Chief Regulatory Officer of TriSalus Life Sciences, reports the acquisition of 14,481 shares of common stock through a restricted stock unit award.

Bryan F. Cox, Chief of Research at TriSalus Life Sciences, reports the acquisition of 11,450 shares of common stock through a restricted stock unit (RSU) award.

Richard Marshak, Chief Commercial Officer of TriSalus Life Sciences, reports the acquisition of 7,644 shares of common stock and disposal of shares on February 18, 2025, according to a Form 4 filing.

Mary T. Szela, CEO and President of TriSalus Life Sciences, was granted 21,089 shares of common stock on February 18, 2025, which will vest on February 13, 2026, contingent upon continued service.

Jodi Devlin, Chief of Clinical Operations at TriSalus Life Sciences, reports acquiring and disposing of common stock on February 18, 2025, according to a Form 4 filing.

David J. Matlin, a director of TriSalus Life Sciences, reported a change in beneficial ownership on February 10, 2025, due to a reset in the conversion price of Series A Convertible Preferred Stock, leading to an increase in the number of common shares issuable upon conversion.

Mats Wahlstrom, a director and 10% owner of TriSalus Life Sciences, reports an increase in potential common stock holdings due to a reset in the conversion price of Series A Convertible Preferred Stock.

Frankenius Equity AB, a 10% owner of TriSalus Life Sciences, has reported an increase in the number of common stock shares issuable upon conversion of their Series A Convertible Preferred Stock due to a conversion price reset.

James Emmett Young, CFO of TriSalus Life Sciences, purchased 6,000 shares of common stock at $5.65 per share on February 5, 2025.